207 results on '"Sugden PH"'
Search Results
2. P95Effects of dabrafenib and trametinib, cancer therapies that target BRaf and MEK, on cardiac signalling
- Author
-
Clerk, A, Connell, L, Pipe, M, Fuller, SJ, and Sugden, PH
- Published
- 2014
- Full Text
- View/download PDF
3. ACTIVATION OF MITOGEN-ACTIVATED PROTEIN KINASE SUBFAMILIES BY OXIDATIVE STRESS IN THE PERFUSED RAT HEART
- Author
-
Sugden, PH, Fuller, SJ, and Clerk, A
- Published
- 1997
4. MITOGEN-ACTIVATED PROTEIN KINASES ARE ACTIVATED BY OXIDATIVE STRESS AND CYTOKINES IN NEONATAL RAT VENTRICULAR MYOCYTES
- Author
-
Clerk, A and Sugden, PH
- Published
- 1997
5. CLONING AND CHARACTERISATION OF A 1233-RESIDUE MITOGEN-ACTIVATED KINASE KINASE KINASE KINASE 4 (MAP4K4) FROM RAT CARDIOMYOCYTES
- Author
-
Fuller, SJ, primary, Clerk, A, additional, and Sugden, PH, additional
- Published
- 2014
- Full Text
- View/download PDF
6. DISSECTING THE ROLES OF MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) CASCADES IN THE MRNA EXPRESSION RESPONSE TO H2O2 IN CARDIOMYOCYTES
- Author
-
Leonard, SJ, primary, Sugden, PH, additional, and Clerk, A, additional
- Published
- 2014
- Full Text
- View/download PDF
7. EXPRESSION AND ACTIVATION OF CARDIAC PROTEIN KINASES N1 AND N2 (PKN1/2)
- Author
-
Osborne, S, primary, Fuller, SJ, additional, Sugden, PH, additional, and Clerk, A, additional
- Published
- 2014
- Full Text
- View/download PDF
8. Liposomal Transfection of Cultured Cardiac Myocytes with Antisense Oligodeoxynucleotides
- Author
-
Peglennon, Sj Fuller, primary, Bogoyevitch, MA, additional, Sale, EM, additional, Sale, GJ, additional, Sugden, PH, additional, and Poole-Wilson, PA, additional
- Published
- 1995
- Full Text
- View/download PDF
9. Tissue Expression of Endothelin-1 Mrna in Endotoxaemia
- Author
-
Kaddoura, S, primary, Curzen, NP, additional, Firth, J, additional, Sugden, PH, additional, Poole-Wilson, PA, additional, and Evans, TW, additional
- Published
- 1995
- Full Text
- View/download PDF
10. Stimulation of Atrial Natriuretic Factor Promoter Activity by Ras and Raf in Cultured Neonatal Rat Ventricular Myocytes
- Author
-
Fuller, SJ, primary, Gillespie-Brown, J, additional, Marshall, CJ, additional, and Sugden, PH, additional
- Published
- 1995
- Full Text
- View/download PDF
11. Towards a re-definition of 'cardiac hypertrophy' through a rational characterization of left ventricular phenotypes: a position paper of the Working Group 'Myocardial Function' of the ESC.
- Author
-
Knöll R, Iaccarino G, Tarone G, Hilfiker-Kleiner D, Bauersachs J, Leite-Moreira AF, Sugden PH, and Balligand JL
- Published
- 2011
12. No improvement in running?
- Author
-
Sugden Ph
- Subjects
Multidisciplinary - Published
- 1992
13. Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3‘:5‘-monophosphate-dependent protein kinase
- Author
-
Thomas M. Lincoln, Jackie D. Corbin, David A. Flockhart, West L, McCarthy D, and Sugden Ph
- Subjects
Adenosine 3 5 monophosphate ,Biochemistry ,Chemistry ,Protein subunit ,Cell Biology ,Mitogen-activated protein kinase kinase ,Protein kinase A ,Mode of action ,Molecular Biology - Published
- 1978
14. P95 Effects of dabrafenib and trametinib, cancer therapies that target BRaf and MEK, on cardiac signalling.
- Author
-
Clerk, A, Connell, L, Pipe, M, Fuller, SJ, and Sugden, PH
- Subjects
OXIMES ,CELLULAR signal transduction ,PYRIDONE ,DRUG efficacy ,PROTEIN kinases ,HEART cells ,CARDIAC hypertrophy - Abstract
Background: The extracellular signal-regulated kinase (ERK1/2) cascade is implicated in cardioprotection and cardiac hypertrophy. Enhanced ERK1/2 signalling is associated with cancer, particularly in melanoma in which ~50% of cancers result from mutations of the upstream kinase BRaf that signals through MEK to ERK1/2. Inhibitors of BRaf (e.g. dabrafenib, DAB) and/or MEK (trametinib, TRAM) are in clinical use as cancer therapies. Early studies failed to identify BRaf in the heart and, whilst BRaf and MEK inhibitors are known to affect cardiac function, their molecular effects remain to be established. Materials and methods. Expression of BRaf was assessed in neonatal rat cardiomyocytes and adult rat hearts by immunoblotting. BRaf activities were measured following immunoprecipitation. Adult rat hearts were perfused in the Langendorff mode under control conditions, with DAB or TRAM alone, with fibroblast growth factor (FGF) or with FGF in the presence of DAB or TRAM. Signalling through the ERK1/2 cascade and potential off-target effects on the cytoprotective Akt pathway were assessed by immunoblotting. Results and discussion. BRaf protein was detected in extracts from adult rat hearts or cardiomyocytes as a doublet of ~90 kDa (predicted 89 kDa). Activity assays confirmed that BRaf has high basal activity that was further increased by peptide growth factors. Perfusion of rat hearts with DAB inhibited baseline phosphorylation (i.e. activation) of MEK and ERK1/2, whilst TRAM inhibited baseline activation of ERK1/2. These data suggest that BRaf activity is required for basal ERK1/2 activation in the heart. Both inhibitors prevented activation of ERK1/2 and downstream kinases (p90 RSK, p70 S6K) by FGF further indicating that growth factor signalling is mediated by BRaf in the heart. Interestingly, whilst DAB inhibited basal Akt phosphorylation, TRAM enhanced Akt signalling in control and FGF-perfused hearts. Conclusions. BRaf is expressed in cardiomyocytes and adult hearts at significant levels, has high basal activity and is activated by peptide growth factors. BRaf and MEK inhibitors in use for cancer therapy suppress basal and growth factor induced activation of ERK1/2 signalling suggesting that they are likely to have cardiotoxic effects. However, potentially damaging inhibition of ERK1/2 signalling by TRAM may be mitigated in part by enhanced cytoprotection via Akt if this pathway is not compromised. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
15. Effects of left ventricular volume overload on mitochondrial and death-receptor-mediated apoptotic pathways in the transition to heart failure.
- Author
-
Moorjani N, Westaby S, Narula J, Catarino PA, Brittin R, Kemp TJ, Narula N, and Sugden PH
- Published
- 2009
- Full Text
- View/download PDF
16. Mitogen-activated protein kinase signalling in rat hearts during postnatal development: MAPKs, MAP3Ks, MAP4Ks and DUSPs.
- Author
-
Alharbi HO, Sugden PH, and Clerk A
- Abstract
Mammalian cardiomyocytes become terminally-differentiated during the perinatal period. In rodents, cytokinesis ceases after a final division cycle immediately after birth. Nuclear division continues and most cardiomyocytes become binucleated by ∼11 days. Subsequent growth results from an increase in cardiomyocyte size. The mechanisms involved remain under investigation. Mitogen-activated protein kinases (MAPKs) regulate cell growth/death: extracellular signal-regulated kinases 1/2 (ERK1/2) promote proliferation, whilst c-Jun N-terminal kinases (JNKs) and p38-MAPKs respond to cellular stresses. We assessed their regulation in rat hearts during postnatal development (2, 7, 14, and 28 days, 12 weeks) during which time there was rapid, substantial downregulation of mitosis/cytokinesis genes (Cenpa/e/f, Aurkb, Anln, Cdca8, Orc6) with lesser downregulation of DNA replication genes (Orcs1-5, Mcms2-7). MAPK activation was assessed by immunoblotting for total and phosphorylated (activated) kinases. Total ERK1/2 was downregulated, but not JNKs or p38-MAPKs, whilst phosphorylation of all MAPKs increased relative to total protein albeit transiently for JNKs. These profiles differed from activation of Akt (also involved in cardiomyocyte growth). Dual-specificity phosphatases, upstream MAPK kinase kinases (MAP3Ks), and MAP3K kinases (MAP4Ks) identified in neonatal rat cardiomyocytes by RNASeq were differentially regulated during postnatal cardiac development. The MAP3Ks that we could assess by immunoblotting (RAF kinases and Map3k3) showed greater downregulation of the protein than mRNA. MAP3K2/MAP3K3/MAP4K5 were upregulated in human failing heart samples and may be part of the "foetal gene programme" of re-expressed genes in disease. Thus, MAPKs, along with kinases and phosphatases that regulate them, potentially play a significant role in postnatal remodelling of the heart., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Striatin plays a major role in angiotensin II-induced cardiomyocyte and cardiac hypertrophy in mice in vivo.
- Author
-
Cull JJ, Cooper STE, Alharbi HO, Chothani SP, Rackham OJL, Meijles DN, Dash PR, Kerkelä R, Ruparelia N, Sugden PH, and Clerk A
- Subjects
- Animals, Male, Humans, Muscle Proteins metabolism, Muscle Proteins genetics, Ventricular Remodeling, Membrane Proteins genetics, Membrane Proteins metabolism, Mice, Mice, Inbred C57BL, Calmodulin-Binding Proteins, Nerve Tissue Proteins, Angiotensin II pharmacology, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Cardiomegaly genetics, Cardiomegaly pathology, Cardiomegaly metabolism, Cardiomegaly physiopathology, Mice, Knockout
- Abstract
The three striatins (STRN, STRN3, STRN4) form the core of STRiatin-Interacting Phosphatase and Kinase (STRIPAK) complexes. These place protein phosphatase 2A (PP2A) in proximity to protein kinases thereby restraining kinase activity and regulating key cellular processes. Our aim was to establish if striatins play a significant role in cardiac remodelling associated with cardiac hypertrophy and heart failure. All striatins were expressed in control human hearts, with up-regulation of STRN and STRN3 in failing hearts. We used mice with global heterozygote gene deletion to assess the roles of STRN and STRN3 in cardiac remodelling induced by angiotensin II (AngII; 7 days). Using echocardiography, we detected no differences in baseline cardiac function or dimensions in STRN+/- or STRN3+/- male mice (8 weeks) compared with wild-type littermates. Heterozygous gene deletion did not affect cardiac function in mice treated with AngII, but the increase in left ventricle mass induced by AngII was inhibited in STRN+/- (but not STRN3+/-) mice. Histological staining indicated that cardiomyocyte hypertrophy was inhibited. To assess the role of STRN in cardiomyocytes, we converted the STRN knockout line for inducible cardiomyocyte-specific gene deletion. There was no effect of cardiomyocyte STRN knockout on cardiac function or dimensions, but the increase in left ventricle mass induced by AngII was inhibited. This resulted from inhibition of cardiomyocyte hypertrophy and cardiac fibrosis. The data indicate that cardiomyocyte striatin is required for early remodelling of the heart by AngII and identify the striatin-based STRIPAK system as a signalling paradigm in the development of pathological cardiac hypertrophy., (© 2024 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. Cardiomyocyte BRAF is a key signalling intermediate in cardiac hypertrophy in mice.
- Author
-
Alharbi HO, Hardyman MA, Cull JJ, Markou T, Cooper STE, Glennon PE, Fuller SJ, Sugden PH, and Clerk A
- Subjects
- Female, Male, Mice, Animals, Proto-Oncogene Proteins B-raf genetics, Phenylephrine, Tamoxifen pharmacology, Cardiomegaly genetics, Fibrosis, Myocytes, Cardiac, Hypertension
- Abstract
Cardiac hypertrophy is necessary for the heart to accommodate an increase in workload. Physiological, compensated hypertrophy (e.g. with exercise) is reversible and largely due to cardiomyocyte hypertrophy. Pathological hypertrophy (e.g. with hypertension) is associated with additional features including increased fibrosis and can lead to heart failure. RAF kinases (ARAF/BRAF/RAF1) integrate signals into the extracellular signal-regulated kinase 1/2 cascade, a pathway implicated in cardiac hypertrophy, and activation of BRAF in cardiomyocytes promotes compensated hypertrophy. Here, we used mice with tamoxifen-inducible cardiomyocyte-specific BRAF knockout (CM-BRAFKO) to assess the role of BRAF in hypertension-associated cardiac hypertrophy induced by angiotensin II (AngII; 0.8 mg/kg/d, 7 d) and physiological hypertrophy induced by phenylephrine (40 mg/kg/d, 7 d). Cardiac dimensions/functions were measured by echocardiography with histological assessment of cellular changes. AngII promoted cardiomyocyte hypertrophy and increased fibrosis within the myocardium (interstitial) and around the arterioles (perivascular) in male mice; cardiomyocyte hypertrophy and interstitial (but not perivascular) fibrosis were inhibited in mice with CM-BRAFKO. Phenylephrine had a limited effect on fibrosis but promoted cardiomyocyte hypertrophy and increased contractility in male mice; cardiomyocyte hypertrophy was unaffected in mice with CM-BRAFKO, but the increase in contractility was suppressed and fibrosis increased. Phenylephrine induced a modest hypertrophic response in female mice and, in contrast with the males, tamoxifen-induced loss of cardiomyocyte BRAF reduced cardiomyocyte size, had no effect on fibrosis and increased contractility. The data identify BRAF as a key signalling intermediate in both physiological and pathological hypertrophy in male mice, and highlight the need for independent assessment of gene function in females., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
19. The insulin receptor family in the heart: new light on old insights.
- Author
-
Clerk A and Sugden PH
- Subjects
- Insulin metabolism, Myocytes, Cardiac metabolism, Phosphorylation, Signal Transduction, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Receptor, Insulin genetics, Receptor, Insulin metabolism
- Abstract
Insulin was discovered over 100 years ago. Whilst the first half century defined many of the physiological effects of insulin, the second emphasised the mechanisms by which it elicits these effects, implicating a vast array of G proteins and their regulators, lipid and protein kinases and counteracting phosphatases, and more. Potential growth-promoting and protective effects of insulin on the heart emerged from studies of carbohydrate metabolism in the 1960s, but the insulin receptors (and the related receptor for insulin-like growth factors 1 and 2) were not defined until the 1980s. A related third receptor, the insulin receptor-related receptor remained an orphan receptor for many years until it was identified as an alkali-sensor. The mechanisms by which these receptors and the plethora of downstream signalling molecules confer cardioprotection remain elusive. Here, we review important aspects of the effects of the three insulin receptor family members in the heart. Metabolic studies are set in the context of what is now known of insulin receptor family signalling and the role of protein kinase B (PKB or Akt), and the relationship between this and cardiomyocyte survival versus death is discussed. PKB/Akt phosphorylates numerous substrates with potential for cardioprotection in the contractile cardiomyocytes and cardiac non-myocytes. Our overall conclusion is that the effects of insulin on glucose metabolism that were initially identified remain highly pertinent in managing cardiomyocyte energetics and preservation of function. This alone provides a high level of cardioprotection in the face of pathophysiological stressors such as ischaemia and myocardial infarction., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
20. Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice in vivo.
- Author
-
Clerk A, Meijles DN, Hardyman MA, Fuller SJ, Chothani SP, Cull JJ, Cooper STE, Alharbi HO, Vanezis K, Felkin LE, Markou T, Leonard SJ, Shaw SW, Rackham OJL, Cook SA, Glennon PE, Sheppard MN, Sembrat JC, Rojas M, McTiernan CF, Barton PJ, and Sugden PH
- Subjects
- Animals, Carbamates pharmacology, Carbamates toxicity, Cardiomegaly metabolism, Cell Size drug effects, Cells, Cultured, Dimerization, Gene Knock-In Techniques, Heart Failure pathology, Humans, MAP Kinase Signaling System drug effects, Male, Mice, Mice, Inbred C57BL, Mutation, Missense, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Point Mutation, Protein Conformation drug effects, Protein Interaction Mapping, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins c-raf antagonists & inhibitors, Proto-Oncogene Proteins c-raf biosynthesis, Rats, Rats, Sprague-Dawley, Sulfonamides pharmacology, Sulfonamides toxicity, Cardiomegaly pathology, MAP Kinase Signaling System physiology, Myocytes, Cardiac pathology, Proto-Oncogene Proteins B-raf physiology
- Abstract
The extracellular signal-regulated kinase 1/2 (ERK1/2) cascade promotes cardiomyocyte hypertrophy and is cardioprotective, with the three RAF kinases forming a node for signal integration. Our aims were to determine if BRAF is relevant for human heart failure, whether BRAF promotes cardiomyocyte hypertrophy, and if Type 1 RAF inhibitors developed for cancer (that paradoxically activate ERK1/2 at low concentrations: the 'RAF paradox') may have the same effect. BRAF was up-regulated in heart samples from patients with heart failure compared with normal controls. We assessed the effects of activated BRAF in the heart using mice with tamoxifen-activated Cre for cardiomyocyte-specific knock-in of the activating V600E mutation into the endogenous gene. We used echocardiography to measure cardiac dimensions/function. Cardiomyocyte BRAFV600E induced cardiac hypertrophy within 10 d, resulting in increased ejection fraction and fractional shortening over 6 weeks. This was associated with increased cardiomyocyte size without significant fibrosis, consistent with compensated hypertrophy. The experimental Type 1 RAF inhibitor, SB590885, and/or encorafenib (a RAF inhibitor used clinically) increased ERK1/2 phosphorylation in cardiomyocytes, and promoted hypertrophy, consistent with a 'RAF paradox' effect. Both promoted cardiac hypertrophy in mouse hearts in vivo, with increased cardiomyocyte size and no overt fibrosis. In conclusion, BRAF potentially plays an important role in human failing hearts, activation of BRAF is sufficient to induce hypertrophy, and Type 1 RAF inhibitors promote hypertrophy via the 'RAF paradox'. Cardiac hypertrophy resulting from these interventions was not associated with pathological features, suggesting that Type 1 RAF inhibitors may be useful to boost cardiomyocyte function., (© 2022 The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
21. The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension.
- Author
-
Meijles DN, Cull JJ, Cooper STE, Markou T, Hardyman MA, Fuller SJ, Alharbi HO, Haines ZHR, Alcantara-Alonso V, Glennon PE, Sheppard MN, Sugden PH, and Clerk A
- Subjects
- Animals, Cardiomegaly physiopathology, Disease Models, Animal, Hypertension physiopathology, Mice, Inbred C57BL, Myocardium pathology, Myocytes, Cardiac metabolism, Rats, Signal Transduction drug effects, Ventricular Remodeling drug effects, Mice, Antineoplastic Agents pharmacology, Fibrosis drug therapy, Hypertension drug therapy, Imidazoles pharmacology, Oximes pharmacology
- Abstract
Raf kinases signal via extracellular signal-regulated kinases 1/2 (ERK1/2) to drive cell division. Since activating mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) are highly oncogenic, BRAF inhibitors including dabrafenib have been developed for cancer. Inhibitors of ERK1/2 signalling used for cancer are cardiotoxic in some patients, raising the question of whether dabrafenib is cardiotoxic. In the heart, ERK1/2 signalling promotes not only cardiomyocyte hypertrophy and is cardioprotective but also promotes fibrosis. Our hypothesis is that ERK1/2 signalling is not required in a non-stressed heart but is required for cardiac remodelling. Thus, dabrafenib may affect the heart in the context of, for example, hypertension. In experiments with cardiomyocytes, cardiac fibroblasts and perfused rat hearts, dabrafenib inhibited ERK1/2 signalling. We assessed the effects of dabrafenib (3 mg/kg/d) on male C57BL/6J mouse hearts in vivo. Dabrafenib alone had no overt effects on cardiac function/dimensions (assessed by echocardiography) or cardiac architecture. In mice treated with 0.8 mg/kg/d angiotensin II (AngII) to induce hypertension, dabrafenib inhibited ERK1/2 signalling and suppressed cardiac hypertrophy in both acute (up to 7 d) and chronic (28 d) settings, preserving ejection fraction. At the cellular level, dabrafenib inhibited AngII-induced cardiomyocyte hypertrophy, reduced expression of hypertrophic gene markers and almost completely eliminated the increase in cardiac fibrosis both in interstitial and perivascular regions. Dabrafenib is not overtly cardiotoxic. Moreover, it inhibits maladaptive hypertrophy resulting from AngII-induced hypertension. Thus, Raf is a potential therapeutic target for hypertensive heart disease and drugs such as dabrafenib, developed for cancer, may be used for this purpose., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
22. MAP4K4 expression in cardiomyocytes: multiple isoforms, multiple phosphorylations and interactions with striatins.
- Author
-
Fuller SJ, Edmunds NS, McGuffin LJ, Hardyman MA, Cull JJ, Alharbi HO, Meijles DN, Sugden PH, and Clerk A
- Subjects
- Amino Acid Sequence, Animals, Calmodulin-Binding Proteins genetics, Female, HEK293 Cells, Humans, Intracellular Signaling Peptides and Proteins genetics, JNK Mitogen-Activated Protein Kinases genetics, Membrane Proteins genetics, Nerve Tissue Proteins genetics, Phosphorylation, Protein Conformation, Protein Interaction Domains and Motifs, Protein Isoforms, Protein Serine-Threonine Kinases genetics, Rats, Rats, Sprague-Dawley, Sequence Homology, Alternative Splicing, Calmodulin-Binding Proteins metabolism, Intracellular Signaling Peptides and Proteins metabolism, JNK Mitogen-Activated Protein Kinases metabolism, Membrane Proteins metabolism, Mutation, Myocytes, Cardiac metabolism, Nerve Tissue Proteins metabolism, Protein Serine-Threonine Kinases metabolism
- Abstract
The Ser/Thr kinase MAP4K4, like other GCKIV kinases, has N-terminal kinase and C-terminal citron homology (CNH) domains. MAP4K4 can activate c-Jun N-terminal kinases (JNKs), and studies in the heart suggest it links oxidative stress to JNKs and heart failure. In other systems, MAP4K4 is regulated in striatin-interacting phosphatase and kinase (STRIPAK) complexes, in which one of three striatins tethers PP2A adjacent to a kinase to keep it dephosphorylated and inactive. Our aim was to understand how MAP4K4 is regulated in cardiomyocytes. The rat MAP4K4 gene was not properly defined. We identified the first coding exon of the rat gene using 5'-RACE, we cloned the full-length sequence and confirmed alternative-splicing of MAP4K4 in rat cardiomyocytes. We identified an additional α-helix C-terminal to the kinase domain important for kinase activity. In further studies, FLAG-MAP4K4 was expressed in HEK293 cells or cardiomyocytes. The Ser/Thr protein phosphatase inhibitor calyculin A (CalA) induced MAP4K4 hyperphosphorylation, with phosphorylation of the activation loop and extensive phosphorylation of the linker between the kinase and CNH domains. This required kinase activity. MAP4K4 associated with myosin in untreated cardiomyocytes, and this was lost with CalA-treatment. FLAG-MAP4K4 associated with all three striatins in cardiomyocytes, indicative of regulation within STRIPAK complexes and consistent with activation by CalA. Computational analysis suggested the interaction was direct and mediated via coiled-coil domains. Surprisingly, FLAG-MAP4K4 inhibited JNK activation by H2O2 in cardiomyocytes and increased myofibrillar organisation. Our data identify MAP4K4 as a STRIPAK-regulated kinase in cardiomyocytes, and suggest it regulates the cytoskeleton rather than activates JNKs., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
23. The insulin receptor family and protein kinase B (Akt) are activated in the heart by alkaline pH and α1-adrenergic receptors.
- Author
-
Meijles DN, Fuller SJ, Cull JJ, Alharbi HO, Cooper STE, Sugden PH, and Clerk A
- Subjects
- Animals, Animals, Newborn, Female, Fibrosis chemically induced, Fibrosis metabolism, Humans, Hydrogen-Ion Concentration, Hypertrophy chemically induced, Hypertrophy metabolism, Imidazoles pharmacology, Insulin metabolism, MAP Kinase Signaling System drug effects, Male, Mice, Mice, Inbred C57BL, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Phosphorylation, Proto-Oncogene Proteins c-akt genetics, Pyrazines pharmacology, Rats, Rats, Sprague-Dawley, Receptor, Insulin genetics, Receptors, Adrenergic, alpha-1 genetics, Alkalies pharmacology, Fibrosis pathology, Hypertrophy pathology, Myocytes, Cardiac pathology, Proto-Oncogene Proteins c-akt metabolism, Receptor, Insulin metabolism, Receptors, Adrenergic, alpha-1 metabolism
- Abstract
Insulin and insulin-like growth factor stimulate protein synthesis and cardioprotection in the heart, acting through their receptors (INSRs, IGF1Rs) and signalling via protein kinase B (PKB, also known as Akt). Protein synthesis is increased in hearts perfused at alkaline pHo to the same extent as with insulin. Moreover, α1-adrenergic receptor (α1-AR) agonists (e.g. phenylephrine) increase protein synthesis in cardiomyocytes, activating PKB/Akt. In both cases, the mechanisms are not understood. Our aim was to determine if insulin receptor-related receptors (INSRRs, activated in kidney by alkaline pH) may account for the effects of alkaline pHo on cardiac protein synthesis, and establish if α1-ARs signal through the insulin receptor family. Alkaline pHo activated PKB/Akt signalling to the same degree as insulin in perfused adult male rat hearts. INSRRs were expressed in rat hearts and, by immunoblotting for phosphorylation (activation) of INSRRs/INSRs/IGF1Rs, we established that INSRRs, together with INSRs/IGF1Rs, are activated by alkaline pHo. The INSRR/INSR/IGF1R kinase inhibitor, linsitinib, prevented PKB/Akt activation by alkaline pHo, indicating that INSRRs/INSRs/IGF1Rs are required. Activation of PKB/Akt in cardiomyocytes by α1-AR agonists was also inhibited by linsitinib. Furthermore, linsitinib inhibited cardiomyocyte hypertrophy induced by α1-ARs in cultured cells, reduced the initial cardiac adaptation (24 h) to phenylephrine in vivo (assessed by echocardiography) and increased cardiac fibrosis over 4 days. We conclude that INSRRs are expressed in the heart and, together with INSRs/IGF1Rs, the insulin receptor family provide a potent system for promoting protein synthesis and cardioprotection. Moreover, this system is required for adaptive hypertrophy induced by α1-ARs., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
24. Redox Regulation of Cardiac ASK1 (Apoptosis Signal-Regulating Kinase 1) Controls p38-MAPK (Mitogen-Activated Protein Kinase) and Orchestrates Cardiac Remodeling to Hypertension.
- Author
-
Meijles DN, Cull JJ, Markou T, Cooper STE, Haines ZHR, Fuller SJ, O'Gara P, Sheppard MN, Harding SE, Sugden PH, and Clerk A
- Subjects
- Animals, Benzamides pharmacology, Heart drug effects, Hydrogen Peroxide pharmacology, Imidazoles pharmacology, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Oxidation-Reduction, Oxidative Stress drug effects, Protein Kinase Inhibitors pharmacology, Pyridines pharmacology, Rats, Reactive Oxygen Species metabolism, Signal Transduction drug effects, Signal Transduction physiology, Ventricular Remodeling drug effects, Hypertension metabolism, MAP Kinase Kinase Kinase 5 metabolism, Myocardium metabolism, Ventricular Remodeling physiology, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Systemic hypertension increases cardiac workload causing cardiomyocyte hypertrophy and increased cardiac fibrosis. An underlying feature is increased production of reactive oxygen species. Redox-sensitive ASK1 (apoptosis signal-regulating kinase 1) activates stress-regulated protein kinases (p38-MAPK [mitogen-activated protein kinases] and JNKs [c-Jun N-terminal kinases]) and promotes fibrosis in various tissues. Here, we determined the specificity of ASK1 signaling in the heart, with the hypothesis that ASK1 inhibitors may be used to manage fibrosis in hypertensive heart disease. Using immunoblotting, we established that moderate levels of H
2 O2 activate ASK1 in neonatal rat cardiomyocytes and perfused rat hearts. ASK1 was activated during ischemia in adult rat hearts, but not on reperfusion, consistent with activation by moderate (not high) reactive oxygen species levels. In contrast, IL (interleukin)-1β activated an alternative kinase, TAK1 (transforming growth factor-activated kinase 1). ASK1 was not activated by IL1β in cardiomyocytes and activation in perfused hearts was due to increased reactive oxygen species. Selonsertib (ASK1 inhibitor) prevented activation of p38-MAPKs (but not JNKs) by oxidative stresses in cultured cardiomyocytes and perfused hearts. In vivo (C57Bl/6J mice with osmotic minipumps for drug delivery), selonsertib (4 mg/[kg·d]) alone did not affect cardiac function/dimensions (assessed by echocardiography). However, it suppressed hypertension-induced cardiac hypertrophy resulting from angiotensin II (0.8 mg/[kg·d], 7d), with inhibition of Nppa/Nppb mRNA upregulation, reduced cardiomyocyte hypertrophy and, notably, significant reductions in interstitial and perivascular fibrosis. Our data identify a specific reactive oxygen species→ASK1→p38-MAPK pathway in the heart and establish that ASK1 inhibitors protect the heart from hypertension-induced cardiac remodeling. Thus, targeting the ASK1→p38-MAPK nexus has potential therapeutic viability as a treatment for hypertensive heart disease.- Published
- 2020
- Full Text
- View/download PDF
25. The cardiomyocyte "redox rheostat": Redox signalling via the AMPK-mTOR axis and regulation of gene and protein expression balancing survival and death.
- Author
-
Meijles DN, Zoumpoulidou G, Markou T, Rostron KA, Patel R, Lay K, Handa BS, Wong B, Sugden PH, and Clerk A
- Subjects
- Adenosine Triphosphate metabolism, Animals, Animals, Newborn, Cell Survival drug effects, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Cytoprotection drug effects, Doxorubicin pharmacology, Enzyme Activation drug effects, Genes, Immediate-Early, Hydrogen Peroxide metabolism, Mechanistic Target of Rapamycin Complex 1 metabolism, Myocytes, Cardiac drug effects, Oxidation-Reduction, Phosphorylation drug effects, Polyribosomes metabolism, Protein Biosynthesis drug effects, Proto-Oncogene Proteins c-akt metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Sprague-Dawley, Stress, Physiological drug effects, AMP-Activated Protein Kinases metabolism, Apoptosis drug effects, Gene Expression Regulation, Myocytes, Cardiac cytology, Myocytes, Cardiac metabolism, Signal Transduction drug effects, TOR Serine-Threonine Kinases metabolism
- Abstract
Reactive oxygen species (ROS) play a key role in development of heart failure but, at a cellular level, their effects range from cytoprotection to induction of cell death. Understanding how this is regulated is crucial to develop novel strategies to ameliorate only the detrimental effects. Here, we revisited the fundamental hypothesis that the level of ROS per se is a key factor in the cellular response by applying different concentrations of H
2 O2 to cardiomyocytes. High concentrations rapidly reduced intracellular ATP and inhibited protein synthesis. This was associated with activation of AMPK which phosphorylated and inhibited Raptor, a crucial component of mTOR complex-1 that regulates protein synthesis. Inhibition of protein synthesis by high concentrations of H2 O2 prevents synthesis of immediate early gene products required for downstream gene expression, and such mRNAs (many encoding proteins required to deal with oxidant stress) were only induced by lower concentrations. Lower concentrations of H2 O2 promoted mTOR phosphorylation, associated with differential recruitment of some mRNAs to the polysomes for translation. Some of the upregulated genes induced by low H2 O2 levels are cytoprotective. We identified p21Cip1/WAF1 as one such protein, and preventing its upregulation enhanced the rate of cardiomyocyte apoptosis. The data support the concept of a "redox rheostat" in which different degrees of ROS influence cell energetics and intracellular signalling pathways to regulate mRNA and protein expression. This sliding scale determines cell fate, modulating survival vs death., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
26. Cardiac protein kinases: the cardiomyocyte kinome and differential kinase expression in human failing hearts.
- Author
-
Fuller SJ, Osborne SA, Leonard SJ, Hardyman MA, Vaniotis G, Allen BG, Sugden PH, and Clerk A
- Subjects
- Animals, Female, Gene Expression Profiling, Humans, Proteomics, RNA, Messenger analysis, Rats, Rats, Sprague-Dawley, Heart Failure enzymology, Myocytes, Cardiac enzymology, Protein Kinases genetics
- Abstract
Aims: Protein kinases are potential therapeutic targets for heart failure, but most studies of cardiac protein kinases derive from other systems, an approach that fails to account for specific kinases expressed in the heart and the contractile cardiomyocytes. We aimed to define the cardiomyocyte kinome (i.e. the protein kinases expressed in cardiomyocytes) and identify kinases with altered expression in human failing hearts., Methods and Results: Expression profiling (Affymetrix microarrays) detected >400 protein kinase mRNAs in rat neonatal ventricular myocytes (NVMs) and/or adult ventricular myocytes (AVMs), 32 and 93 of which were significantly up-regulated or down-regulated (greater than two-fold), respectively, in AVMs. Data for AGC family members were validated by qPCR. Proteomics analysis identified >180 cardiomyocyte protein kinases, with high relative expression of mitogen-activated protein kinase cascades and other known cardiomyocyte kinases (e.g. CAMKs, cAMP-dependent protein kinase). Other kinases are poorly investigated (e.g. Slk, Stk24, Oxsr1). Expression of Akt1/2/3, BRaf, ERK1/2, Map2k1, Map3k8, Map4k4, MST1/3, p38-MAPK, PKCδ, Pkn2, Ripk1/2, Tnni3k, and Zak was confirmed by immunoblotting. Relative to total protein, Map3k8 and Tnni3k were up-regulated in AVMs vs. NVMs. Microarray data for human hearts demonstrated variation in kinome expression that may influence responses to kinase inhibitor therapies. Furthermore, some kinases were up-regulated (e.g. NRK, JAK2, STK38L) or down-regulated (e.g. MAP2K1, IRAK1, STK40) in human failing hearts., Conclusion: This characterization of the spectrum of kinases expressed in cardiomyocytes and the heart (cardiomyocyte and cardiac kinomes) identified novel kinases, some of which are differentially expressed in failing human hearts and could serve as potential therapeutic targets., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
27. SOcK, MiSTs, MASK and STicKs: the GCKIII (germinal centre kinase III) kinases and their heterologous protein-protein interactions.
- Author
-
Sugden PH, McGuffin LJ, and Clerk A
- Subjects
- Adaptor Proteins, Signal Transducing chemistry, Adaptor Proteins, Signal Transducing genetics, Adaptor Proteins, Signal Transducing metabolism, Amino Acid Sequence, Animals, Germinal Center Kinases, Humans, Molecular Sequence Data, Protein Serine-Threonine Kinases genetics, Protein Interaction Domains and Motifs genetics, Protein Serine-Threonine Kinases chemistry, Protein Serine-Threonine Kinases metabolism
- Abstract
The GCKIII (germinal centre kinase III) subfamily of the mammalian Ste20 (sterile 20)-like group of serine/threonine protein kinases comprises SOK1 (Ste20-like/oxidant-stress-response kinase 1), MST3 (mammalian Ste20-like kinase 3) and MST4. Initially, GCKIIIs were considered in the contexts of the regulation of mitogen-activated protein kinase cascades and apoptosis. More recently, their participation in multiprotein heterocomplexes has become apparent. In the present review, we discuss the structure and phosphorylation of GCKIIIs and then focus on their interactions with other proteins. GCKIIIs possess a highly-conserved, structured catalytic domain at the N-terminus and a less-well conserved C-terminal regulatory domain. GCKIIIs are activated by tonic autophosphorylation of a T-loop threonine residue and their phosphorylation is regulated primarily through protein serine/threonine phosphatases [especially PP2A (protein phosphatase 2A)]. The GCKIII regulatory domains are highly disorganized, but can interact with more structured proteins, particularly the CCM3 (cerebral cavernous malformation 3)/PDCD10 (programmed cell death 10) protein. We explore the role(s) of GCKIIIs (and CCM3/PDCD10) in STRIPAK (striatin-interacting phosphatase and kinase) complexes and their association with the cis-Golgi protein GOLGA2 (golgin A2; GM130). Recently, an interaction of GCKIIIs with MO25 has been identified. This exhibits similarities to the STRADα (STE20-related kinase adaptor α)-MO25 interaction (as in the LKB1-STRADα-MO25 heterotrimer) and, at least for MST3, the interaction may be enhanced by cis-autophosphorylation of its regulatory domain. In these various heterocomplexes, GCKIIIs associate with the Golgi apparatus, the centrosome and the nucleus, as well as with focal adhesions and cell junctions, and are probably involved in cell migration, polarity and proliferation. Finally, we consider the association of GCKIIIs with a number of human diseases, particularly cerebral cavernous malformations.
- Published
- 2013
- Full Text
- View/download PDF
28. p90 ribosomal S6 kinases play a significant role in early gene regulation in the cardiomyocyte response to G(q)-protein-coupled receptor stimuli, endothelin-1 and α(1)-adrenergic receptor agonists.
- Author
-
Amirak E, Fuller SJ, Sugden PH, and Clerk A
- Subjects
- Adrenergic alpha-Agonists metabolism, Animals, Benzamides pharmacology, Cell Nucleus metabolism, Male, Mitogen-Activated Protein Kinase 3 genetics, Mitogen-Activated Protein Kinase 3 metabolism, Myocytes, Cardiac cytology, RNA metabolism, Rats, Rats, Sprague-Dawley, Receptor, Endothelin A metabolism, Ribosomal Protein S6 Kinases, 90-kDa genetics, Signal Transduction, Adrenergic alpha-Agonists pharmacology, Gene Expression Regulation, Myocytes, Cardiac metabolism, Receptor, Endothelin A agonists, Receptors, Adrenergic, alpha-1 metabolism, Ribosomal Protein S6 Kinases, 90-kDa metabolism
- Abstract
ERK1/2 (extracellular-signal-regulated kinase 1/2) and their substrates RSKs (p90 ribosomal S6 kinases) phosphorylate different transcription factors, contributing differentially to transcriptomic profiles. In cardiomyocytes ERK1/2 are required for >70% of the transcriptomic response to endothelin-1. In the present study we investigated the role of RSKs in the transcriptomic responses to the G(q)-protein-coupled receptor agonists endothelin-1, phenylephrine (a generic α(1)-adrenergic receptor agonist) and A61603 (α(1A)-adrenergic receptor selective). Phospho-ERK1/2 and phospho-RSKs appeared in cardiomyocyte nuclei within 2-3 min of stimulation (endothelin-1>A61603≈phenylephrine). All agonists increased nuclear RSK2, but only endothelin-1 increased the nuclear RSK1 content. PD184352 (inhibits ERK1/2 activation) and BI-D1870 (inhibits RSKs) were used to dissect the contribution of RSKs to the endothelin-1-responsive transcriptome. Of the 213 RNAs up-regulated after 1 h, 51% required RSKs for their up-regulation, whereas 29% required ERK1/2 but not RSKs. The transcriptomic response to phenylephrine overlapped with, but was not identical with, endothelin-1. As with endothelin-1, PD184352 inhibited the up-regulation of most phenylephrine-responsive transcripts, but the greater variation in the effects of BI-D1870 suggests that differential RSK signalling influences global gene expression. A61603 induced similar changes in RNA expression in cardiomyocytes as phenylephrine, indicating that the signal was mediated largely through α(1A)-adrenergic receptors. A61603 also increased expression of immediate early genes in perfused adult rat hearts and, as in cardiomyocytes, up-regulation of the majority of genes was inhibited by PD184352. PD184352 or BI-D1870 prevented the increased surface area induced by endothelin-1 in cardiomyocytes. Thus RSKs play a significant role in regulating cardiomyocyte gene expression and hypertrophy in response to G(q)-protein-coupled receptor stimulation.
- Published
- 2013
- Full Text
- View/download PDF
29. The early transcriptomic response to interleukin 1β and interleukin 33 in rat neonatal cardiomyocytes.
- Author
-
Barrett OP, Yndestad A, Marshall AK, Sugden PH, and Clerk A
- Subjects
- Animals, Animals, Newborn, Gene Expression Regulation drug effects, Interleukin-33, Myocytes, Cardiac drug effects, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Transcriptome drug effects, Interleukin-1beta pharmacology, Interleukins pharmacology, Myocytes, Cardiac metabolism, Transcriptome genetics
- Abstract
In the heart, inflammatory cytokines including interleukin (IL) 1β are implicated in regulating adaptive and maladaptive changes, whereas IL33 negatively regulates cardiomyocyte hypertrophy and promotes cardioprotection. These agonists signal through a common co-receptor but, in cardiomyocytes, IL1β more potently activates mitogen-activated protein kinases and NFκB, pathways that regulate gene expression. We compared the effects of external application of IL1β and IL33 on the cardiomyocyte transcriptome. Neonatal rat cardiomyocytes were exposed to IL1β or IL33 (0.5, 1 or 2h). Transcriptomic profiles were determined using Affymetrix rat genome 230 2.0 microarrays and data were validated by quantitative PCR. IL1β induced significant changes in more RNAs than IL33 and, generally, to a greater degree. It also had a significantly greater effect in downregulating mRNAs and in regulating mRNAs associated with selected pathways. IL33 had a greater effect on a small, select group of specific transcripts. Thus, differences in intensity of intracellular signals can deliver qualitatively different responses. Quantitatively different responses in production of receptor agonists and transcription factors may contribute to qualitative differences at later times resulting in different phenotypic cellular responses., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
30. Feedback regulation by Atf3 in the endothelin-1-responsive transcriptome of cardiomyocytes: Egr1 is a principal Atf3 target.
- Author
-
Giraldo A, Barrett OP, Tindall MJ, Fuller SJ, Amirak E, Bhattacharya BS, Sugden PH, and Clerk A
- Subjects
- Activating Transcription Factor 3 deficiency, Activating Transcription Factor 3 genetics, Animals, Animals, Newborn, Base Sequence, Cells, Cultured, Cyclooxygenase 2 biosynthesis, Early Growth Response Protein 1 antagonists & inhibitors, Early Growth Response Protein 1 biosynthesis, Feedback, Physiological drug effects, Hypertrophy, Left Ventricular genetics, Hypertrophy, Left Ventricular metabolism, Hypertrophy, Left Ventricular pathology, Molecular Sequence Data, Myocytes, Cardiac drug effects, Rats, Rats, Sprague-Dawley, Transcriptome drug effects, Up-Regulation genetics, Activating Transcription Factor 3 physiology, Early Growth Response Protein 1 metabolism, Endothelin-1 physiology, Feedback, Physiological physiology, Gene Targeting methods, Myocytes, Cardiac metabolism, Myocytes, Cardiac pathology, Transcriptome genetics
- Abstract
Endothelin-1 promotes cardiomyocyte hypertrophy by inducing changes in gene expression. Immediate early genes including Atf3 (activating transcription factor 3), Egr1 (early growth response 1) and Ptgs2 (prostaglandin-endoperoxide synthase 2) are rapidly and transiently up-regulated by endothelin-1 in cardiomyocytes. Atf3 regulates the expression of downstream genes and is implicated in negative feedback regulation of other immediate early genes. To identify Atf3-regulated genes, we knocked down Atf3 expression in cardiomyocytes exposed to endothelin-1 and used microarrays to interrogate the transcriptomic effects. The expression of 23 mRNAs (including Egr1 and Ptgs2) was enhanced and the expression of 25 mRNAs was inhibited by Atf3 knockdown. Using quantitative PCR, we determined that knockdown of Atf3 had little effect on up-regulation of Egr1 mRNA over 30 min, but abolished the subsequent decline, causing sustained Egr1 mRNA expression and enhanced protein expression. This resulted from direct binding of Atf3 to the Egr1 promoter. Mathematical modelling established that Atf3 can suffice to suppress Egr1 expression. Given the widespread co-regulation of Atf3 with Egr1, we suggest that the Atf3-Egr1 negative feedback loop is of general significance. Loss of Atf3 caused abnormal cardiomyocyte growth, presumably resulting from the dysregulation of target genes. The results of the present study therefore identify Atf3 as a nexus in cardiomyocyte hypertrophy required to facilitate the full and proper growth response.
- Published
- 2012
- Full Text
- View/download PDF
31. A novel non-canonical mechanism of regulation of MST3 (mammalian Sterile20-related kinase 3).
- Author
-
Fuller SJ, McGuffin LJ, Marshall AK, Giraldo A, Pikkarainen S, Clerk A, and Sugden PH
- Subjects
- Amino Acid Sequence, Animals, Catalytic Domain, Humans, Mammals, Molecular Sequence Data, Muscle Cells metabolism, Nerve Tissue Proteins metabolism, Phosphorylation, Protein Phosphatase 2 genetics, Protein Phosphatase 2 metabolism, Protein Serine-Threonine Kinases metabolism, Rats, Threonine genetics, Nerve Tissue Proteins genetics, Protein Serine-Threonine Kinases genetics
- Abstract
The canonical pathway of regulation of the GCK (germinal centre kinase) III subgroup member, MST3 (mammalian Sterile20-related kinase 3), involves a caspase-mediated cleavage between N-terminal catalytic and C-terminal regulatory domains with possible concurrent autophosphorylation of the activation loop MST3(Thr(178)), induction of serine/threonine protein kinase activity and nuclear localization. We identified an alternative 'non-canonical' pathway of MST3 activation (regulated primarily through dephosphorylation) which may also be applicable to other GCKIII (and GCKVI) subgroup members. In the basal state, inactive MST3 co-immunoprecipitated with the Golgi protein GOLGA2/gm130 (golgin A2/Golgi matrix protein 130). Activation of MST3 by calyculin A (a protein serine/threonine phosphatase 1/2A inhibitor) stimulated (auto)phosphorylation of MST3(Thr(178)) in the catalytic domain with essentially simultaneous cis-autophosphorylation of MST3(Thr(328)) in the regulatory domain, an event also requiring the MST3(341-376) sequence which acts as a putative docking domain. MST3(Thr(178)) phosphorylation increased MST3 kinase activity, but this activity was independent of MST3(Thr(328)) phosphorylation. Interestingly, MST3(Thr(328)) lies immediately C-terminal to a STRAD (Sterile20-related adaptor) pseudokinase-like site identified recently as being involved in binding of GCKIII/GCKVI members to MO25 scaffolding proteins. MST3(Thr(178)/Thr(328)) phosphorylation was concurrent with dissociation of MST3 from GOLGA2/gm130 and association of MST3 with MO25, and MST3(Thr(328)) phosphorylation was necessary for formation of the activated MST3-MO25 holocomplex.
- Published
- 2012
- Full Text
- View/download PDF
32. Actions and interactions of AMPK with insulin, the peroxisomal-proliferator activated receptors and sirtuins.
- Author
-
Holness MJ, Sugden PH, Silvestre MF, and Sugden MC
- Abstract
AMP-activated protein kinase (AMPK) activity responds to a requirement to increase cellular ATP production and/or to conserve available ATP. AMPK is therefore central to the mechanisms of adjustment to fluctuating energy demand or metabolic substrate supply. AMPK has important actions in several insulin-responsive tissues, as well as in the pancreatic β cell, through which it can modulate glycemic control, insulin action and metabolic substrate selection and disposal. We review recent novel findings elucidating the mechanisms by which AMPK activation can correct impaired insulin action. However, we also emphasize not only the similarities, but also the differences in the actions of insulin and AMPK. We focus on metabolic interfaces between AMPK, peroxisomal proliferator-activated receptors, sirtuins and mTORC.
- Published
- 2012
- Full Text
- View/download PDF
33. MICAL-1 is a negative regulator of MST-NDR kinase signaling and apoptosis.
- Author
-
Zhou Y, Adolfs Y, Pijnappel WW, Fuller SJ, Van der Schors RC, Li KW, Sugden PH, Smit AB, Hergovich A, and Pasterkamp RJ
- Subjects
- Adaptor Proteins, Signal Transducing, Animals, Base Sequence, Blotting, Western, COS Cells, Chlorocebus aethiops, Cytoskeletal Proteins genetics, Cytoskeletal Proteins metabolism, HEK293 Cells, Humans, Immunoprecipitation, Intracellular Signaling Peptides and Proteins genetics, Intracellular Signaling Peptides and Proteins metabolism, L Cells, LIM Domain Proteins, Mice, Mice, Knockout, Microfilament Proteins, Microtubule-Associated Proteins genetics, Mixed Function Oxygenases genetics, Phosphorylation, Protein Binding, Protein Serine-Threonine Kinases genetics, RNA Interference, Apoptosis, Microtubule-Associated Proteins metabolism, Mixed Function Oxygenases metabolism, Protein Serine-Threonine Kinases metabolism, Signal Transduction
- Abstract
MICALs (molecules interacting with CasL) are atypical multidomain flavoenzymes with diverse cellular functions. The molecular pathways employed by MICAL proteins to exert their cellular effects remain largely uncharacterized. Via an unbiased proteomics approach, we identify MICAL-1 as a binding partner of NDR (nuclear Dbf2-related) kinases. NDR1/2 kinases are known to mediate apoptosis downstream of the mammalian Ste-20-like kinase MST1, and ablation of NDR1 in mice predisposes the mice to cancer as a result of compromised apoptosis. MST1 phosphorylates NDR1/2 kinases at their hydrophobic motif, thereby facilitating full NDR kinase activity and function. However, if and how this key phosphorylation event is regulated are unknown. Here we show that MICAL-1 interacts with the hydrophobic motif of NDR1/2 and that overexpression or knockdown of MICAL-1 reduces or augments NDR kinase activation or activity, respectively. Surprisingly, MICAL-1 is a phosphoprotein but not an NDR or MST1 substrate. Rather, MICAL-1 competes with MST1 for NDR binding and thereby antagonizes MST1-induced NDR activation. In line with this inhibitory effect, overexpression or knockdown of MICAL-1 inhibits or enhances, respectively, NDR-dependent proapoptotic signaling induced by extrinsic stimuli. Our findings unveil a previously unknown biological role for MICAL-1 in apoptosis and define a novel negative regulatory mechanism of MST-NDR signaling.
- Published
- 2011
- Full Text
- View/download PDF
34. Conditional transgenic expression of fibroblast growth factor 9 in the adult mouse heart reduces heart failure mortality after myocardial infarction.
- Author
-
Korf-Klingebiel M, Kempf T, Schlüter KD, Willenbockel C, Brod T, Heineke J, Schmidt VJ, Jantzen F, Brandes RP, Sugden PH, Drexler H, Molkentin JD, and Wollert KC
- Subjects
- Animals, Bone Morphogenetic Protein 6 genetics, Bone Morphogenetic Protein 6 metabolism, Fibroblast Growth Factor 9 administration & dosage, Fibroblast Growth Factor 9 genetics, Gene Expression drug effects, Heart, Heart Failure mortality, Hypertrophy, Left Ventricular chemically induced, Mice, Mice, Transgenic, Neovascularization, Pathologic chemically induced, Phosphorylation, Rats, Tetracycline pharmacology, Fibroblast Growth Factor 9 pharmacology, Heart Failure prevention & control, Myocardial Infarction complications
- Abstract
Background: Fibroblast growth factor 9 (FGF9) is secreted from bone marrow cells, which have been shown to improve systolic function after myocardial infarction (MI) in a clinical trial. FGF9 promotes cardiac vascularization during embryonic development but is only weakly expressed in the adult heart., Methods and Results: We used a tetracycline-responsive binary transgene system based on the α-myosin heavy chain promoter to test whether conditional expression of FGF9 in the adult myocardium supports adaptation after MI. In sham-operated mice, transgenic FGF9 stimulated left ventricular hypertrophy with microvessel expansion and preserved systolic and diastolic function. After coronary artery ligation, transgenic FGF9 enhanced hypertrophy of the noninfarcted left ventricular myocardium with increased microvessel density, reduced interstitial fibrosis, attenuated fetal gene expression, and improved systolic function. Heart failure mortality after MI was markedly reduced by transgenic FGF9, whereas rupture rates were not affected. Adenoviral FGF9 gene transfer after MI similarly promoted left ventricular hypertrophy with improved systolic function and reduced heart failure mortality. Mechanistically, FGF9 stimulated proliferation and network formation of endothelial cells but induced no direct hypertrophic effects in neonatal or adult rat cardiomyocytes in vitro. FGF9-stimulated endothelial cell supernatants, however, induced cardiomyocyte hypertrophy via paracrine release of bone morphogenetic protein 6. In accord with this observation, expression of bone morphogenetic protein 6 and phosphorylation of its downstream targets SMAD1/5 were increased in the myocardium of FGF9 transgenic mice., Conclusions: Conditional expression of FGF9 promotes myocardial vascularization and hypertrophy with enhanced systolic function and reduced heart failure mortality after MI. These observations suggest a previously unrecognized therapeutic potential for FGF9 after MI.
- Published
- 2011
- Full Text
- View/download PDF
35. Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1/2) are formed endogenously in intact cardiac myocytes and are enzymically active.
- Author
-
Sugden PH, Markou T, Fuller SJ, Tham el L, Molkentin JD, Paterson HF, and Clerk A
- Subjects
- Animals, Cells, Cultured, Endothelin-1 pharmacology, Enzyme Activation, Myocytes, Cardiac drug effects, Phosphorylation, Rats, Rats, Sprague-Dawley, Signal Transduction, Tetradecanoylphorbol Acetate analogs & derivatives, Tetradecanoylphorbol Acetate pharmacology, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Myocytes, Cardiac enzymology
- Abstract
ERK1 and ERK2 (ERK1/2) are central to the regulation of cell division, growth and survival. They are activated by phosphorylation of the Thr- and the Tyr- residues in their Thr-Glu-Tyr activation loops. The dogma is that dually-phosphorylated ERK1/2 constitute the principal activities in intact cells. We previously showed that, in neonatal rat cardiac myocytes, endothelin-1 and phorbol 12-myristate 13-acetate (PMA) powerfully and rapidly (maximal at ~5 min) activate ERK1/2. Here, we show that dually-phosphorylated ERK1/2 rapidly (< 2 min) appear in the nucleus following stimulation with endothelin-1. We characterized the active ERK1/2 species in myocytes exposed to endothelin-1 or PMA using MonoQ FPLC. Unexpectedly, two peaks of ERK1 and two peaks of ERK2 activity were resolved using in vitro kinase assays. One of each of these represented the dually-phosphorylated species. The other two represented activities for ERK1 or ERK2 which were phosphorylated solely on the Thr- residue. Monophosphothreonyl ERK1/2 represented maximally ~30% of total ERK1/2 activity after stimulation with endothelin-1 or PMA, and their k(cat) values were estimated to be minimally ~30% of the dually-phosphorylated species. Appearance of monophosphothreonyl ERK1/2 was rapid but delayed in comparison with dually-phosphorylated ERK1/2. Of 10 agonists studied, endothelin-1 and PMA were most effective in terms of ERK1/2 activation and in stimulating the appearance of monophosphothreonyl and dually-phosphorylated ERK1/2. Thus, enzymically active monophosphothreonyl ERK1/2 are formed endogenously following activation of the ERK1/2 cascade and we suggest that monophosphothreonyl ERK1/2 arise by protein tyrosine phosphatase-mediated dephosphorylation of dually-phosphorylated ERK1/2., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
36. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.
- Author
-
Eschenhagen T, Force T, Ewer MS, de Keulenaer GW, Suter TM, Anker SD, Avkiran M, de Azambuja E, Balligand JL, Brutsaert DL, Condorelli G, Hansen A, Heymans S, Hill JA, Hirsch E, Hilfiker-Kleiner D, Janssens S, de Jong S, Neubauer G, Pieske B, Ponikowski P, Pirmohamed M, Rauchhaus M, Sawyer D, Sugden PH, Wojta J, Zannad F, and Shah AM
- Subjects
- Anthracyclines adverse effects, Anthracyclines therapeutic use, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antineoplastic Agents therapeutic use, Cardiotoxins, Education, ErbB Receptors drug effects, Europe, Humans, Neoplasms drug therapy, Risk Factors, Sirolimus antagonists & inhibitors, Trastuzumab, Antineoplastic Agents adverse effects, Cardiology standards, Cardiovascular System drug effects, Heart Failure chemically induced, Practice Guidelines as Topic
- Abstract
The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.
- Published
- 2011
- Full Text
- View/download PDF
37. Regulation of the cardiomyocyte transcriptome vs translatome by endothelin-1 and insulin: translational regulation of 5' terminal oligopyrimidine tract (TOP) mRNAs by insulin.
- Author
-
Markou T, Marshall AK, Cullingford TE, Tham el L, Sugden PH, and Clerk A
- Subjects
- 5' Untranslated Regions genetics, Animals, Base Sequence, Computational Biology, Mice, Molecular Sequence Data, Polyribosomes drug effects, Polyribosomes genetics, Polyribosomes metabolism, RNA, Messenger genetics, Rats, Signal Transduction drug effects, Endothelin-1 pharmacology, Gene Expression Profiling, Insulin pharmacology, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Protein Biosynthesis drug effects, RNA 5' Terminal Oligopyrimidine Sequence genetics
- Abstract
Background: Changes in cellular phenotype result from underlying changes in mRNA transcription and translation. Endothelin-1 stimulates cardiomyocyte hypertrophy with associated changes in mRNA/protein expression and an increase in the rate of protein synthesis. Insulin also increases the rate of translation but does not promote overt cardiomyocyte hypertrophy. One mechanism of translational regulation is through 5' terminal oligopyrimidine tracts (TOPs) that, in response to growth stimuli, promote mRNA recruitment to polysomes for increased translation. TOP mRNAs include those encoding ribosomal proteins, but the full panoply remains to be established. Here, we used microarrays to compare the effects of endothelin-1 and insulin on the global transcriptome of neonatal rat cardiomyocytes, and on mRNA recruitment to polysomes (i.e. the translatome)., Results: Globally, endothelin-1 and insulin (1 h) promoted >1.5-fold significant (false discovery rate < 0.05) changes in expression of 341 and 38 RNAs, respectively. For these transcripts with this level of change there was little evidence of translational regulation. However, 1336 and 712 RNAs had >1.25-fold significant changes in expression in total and/or polysomal RNA induced by endothelin-1 or insulin, respectively, of which approximately 35% of endothelin-1-responsive and approximately 56% of insulin-responsive transcripts were translationally regulated. Of mRNAs for established proteins recruited to polysomes in response to insulin, 49 were known TOP mRNAs with a further 15 probable/possible TOP mRNAs, but 49 had no identifiable TOP sequences or other consistent features in the 5' untranslated region., Conclusions: Endothelin-1, rather than insulin, substantially affects global transcript expression to promote cardiomyocyte hypertrophy. Effects on RNA recruitment to polysomes are subtle, with differential effects of endothelin-1 and insulin on specific transcripts. Furthermore, although insulin promotes recruitment of TOP mRNAs to cardiomyocyte polysomes, not all recruited mRNAs are TOP mRNAs.
- Published
- 2010
- Full Text
- View/download PDF
38. ERK1/2 signaling dominates over RhoA signaling in regulating early changes in RNA expression induced by endothelin-1 in neonatal rat cardiomyocytes.
- Author
-
Marshall AK, Barrett OP, Cullingford TE, Shanmugasundram A, Sugden PH, and Clerk A
- Subjects
- Animals, Animals, Newborn, Cells, Cultured, Enzyme Inhibitors pharmacology, Gene Expression Profiling, Hypertrophy, Mitogen-Activated Protein Kinase 1 metabolism, Myocytes, Cardiac pathology, RNA, Messenger biosynthesis, Rats, Time Factors, Endothelin-1 pharmacology, Gene Expression Regulation drug effects, Mitogen-Activated Protein Kinase 3 metabolism, Myocytes, Cardiac metabolism, Signal Transduction, rhoA GTP-Binding Protein metabolism
- Abstract
Background: Cardiomyocyte hypertrophy is associated with changes in gene expression. Extracellular signal-regulated kinases 1/2 (ERK1/2) and RhoA [activated by hypertrophic agonists (e.g. endothelin-1)] regulate gene expression and are implicated in the response, but their relative significance in regulating the cardiomyocyte transcriptome is unknown. Our aim was to establish the significance of ERK1/2 and/or RhoA in the early cardiomyocyte transcriptomic response to endothelin-1., Methods/principal Findings: Cardiomyocytes were exposed to endothelin-1 (1 h) with/without PD184352 (to inhibit ERK1/2) or C3 transferase (C3T, to inhibit RhoA). RNA expression was analyzed using microarrays and qPCR. ERK1/2 signaling positively regulated approximately 65% of the early gene expression response to ET-1 with a small (approximately 2%) negative effect, whereas RhoA signaling positively regulated approximately 10% of the early gene expression response to ET-1 with a greater (approximately 14%) negative contribution. Of RNAs non-responsive to endothelin-1, 66 or 448 were regulated by PD184352 or C3T, respectively, indicating that RhoA had a more significant effect on baseline RNA expression. mRNAs upregulated by endothelin-1 encoded a number of receptor ligands (e.g. Ereg, Areg, Hbegf) and transcription factors (e.g. Abra/Srf) that potentially propagate the response., Conclusions/significance: ERK1/2 dominates over RhoA in the early transcriptomic response to endothelin-1. RhoA plays a major role in maintaining baseline RNA expression but, with upregulation of Abra/Srf by endothelin-1, RhoA may regulate changes in RNA expression over longer times. Our data identify ERK1/2 as a more significant node than RhoA in regulating the early stages of cardiomyocyte hypertrophy.
- Published
- 2010
- Full Text
- View/download PDF
39. Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1.
- Author
-
Yndestad A, Marshall AK, Hodgkinson JD, Tham el L, Sugden PH, and Clerk A
- Subjects
- Animals, Enzyme Activation drug effects, In Vitro Techniques, Inflammation metabolism, Interleukins pharmacology, Oxidative Stress drug effects, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, p38 Mitogen-Activated Protein Kinases metabolism, Endothelin-1 pharmacology, Gene Expression Regulation drug effects, Interleukins genetics, Interleukins metabolism, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Signal Transduction drug effects
- Abstract
The related inflammatory cytokines, interleukin- (IL-) 1beta and IL-33, are both implicated in the response of the heart to injury. They also activate mitogen-activated protein kinases (MAPKs) in cardiac myocytes. The hypertrophic Gq protein-coupled receptor agonist endothelin-1 is a potentially cardioprotective peptide and may modulate the inflammatory response. Endothelin-1 also stimulates (MAPKs) in cardiac myocytes and promotes rapid changes in expression of mRNAs encoding intercellular and intracellular signalling components including receptors for IL-33 (ST2) and phosphoprotein phosphatases. Prior exposure to endothelin-1 may specifically modulate the response to IL-33 and, more globally, influence MAPK activation by different stimuli. Neonatal rat ventricular myocytes were exposed to IL-1beta or IL-33 with or without pre-exposure to endothelin-1 (5h) and MAPK activation assessed. IL-33 activated ERK1/2, JNKs and p38-MAPK, but to a lesser degree than IL-1beta. Endothelin-1 increased expression of soluble IL-33 receptors (sST2 receptors) which may prevent binding of IL-33 to the cell-surface receptors. However, pretreatment with endothelin-1 only inhibited activation of p38-MAPK by IL-33 with no significant influence on ERK1/2 and a small increase in activation of JNKs. Inhibition of p38-MAPK signalling following pretreatment with endothelin-1 was also detected with IL-1beta, H(2)O(2) or tumour necrosis factor alpha (TNFalpha) indicating an effect intrinsic to the signalling pathway. Endothelin-1 pretreatment suppressed the increase in expression of IL-6 mRNA induced by IL-1beta and decreased the duration of expression of TNFalpha mRNA. Coupled with the general decrease in p38-MAPK signalling, we conclude that endothelin-1 attenuates the cardiac myocyte inflammatory response, potentially to confer cardioprotection., (Copyright (c) 2009 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
40. Dying by the way you live: AIF vs. caspases in apoptosis of hypertrophied cardiomyocytes.
- Author
-
Clerk A and Sugden PH
- Subjects
- Animals, DNA Fragmentation, Rats, Apoptosis, Apoptosis Inducing Factor physiology, Cardiomegaly pathology, Caspases physiology, Myocytes, Cardiac pathology
- Published
- 2010
- Full Text
- View/download PDF
41. Regulation of expression of the rat orthologue of mouse double minute 2 (MDM2) by H(2)O(2)-induced oxidative stress in neonatal rat cardiac myocytes.
- Author
-
Pikkarainen S, Kennedy RA, Marshall AK, Tham el L, Lay K, Kriz TA, Handa BS, Clerk A, and Sugden PH
- Subjects
- Animals, Animals, Newborn, Apoptosis drug effects, Apoptosis genetics, Base Sequence, Caspase 3 metabolism, Humans, Introns genetics, Mice, Molecular Sequence Data, Myocytes, Cardiac cytology, Myocytes, Cardiac metabolism, Oxidative Stress genetics, Promoter Regions, Genetic genetics, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Response Elements, Transcription Factor AP-1 genetics, Transcriptional Activation drug effects, Up-Regulation drug effects, Gene Expression Regulation drug effects, Hydrogen Peroxide pharmacology, Myocytes, Cardiac drug effects, Oxidative Stress drug effects, Proto-Oncogene Proteins c-mdm2 genetics, Proto-Oncogene Proteins c-mdm2 metabolism, Sequence Homology, Amino Acid
- Abstract
The Mdm2 ubiquitin ligase is an important regulator of p53 abundance and p53-dependent apoptosis. Mdm2 expression is frequently regulated by a p53 Mdm2 autoregulatory loop whereby p53 stimulates Mdm2 expression and hence its own degradation. Although extensively studied in cell lines, relatively little is known about Mdm2 expression in heart where oxidative stress (exacerbated during ischemia-reperfusion) is an important pro-apoptotic stimulus. We demonstrate that Mdm2 transcript and protein expression are induced by oxidative stress (0.2 mm H(2)O(2)) in neonatal rat cardiac myocytes. In other cells, constitutive Mdm2 expression is regulated by the P1 promoter (5' to exon 1), with inducible expression regulated by the P2 promoter (in intron 1). In myocytes, H(2)O(2) increased Mdm2 expression from the P2 promoter, which contains two p53-response elements (REs), one AP-1 RE, and two Ets REs. H(2)O(2) did not detectably increase expression of p53 mRNA or protein but did increase expression of several AP-1 transcription factors. H(2)O(2) increased binding of AP-1 proteins (c-Jun, JunB, JunD, c-Fos, FosB, and Fra-1) to an Mdm2 AP-1 oligodeoxynucleotide probe, and chromatin immunoprecipitation assays showed it increased binding of c-Jun or JunB to the P2 AP-1 RE. Finally, antisense oligonucleotide-mediated reduction of H(2)O(2)-induced Mdm2 expression increased caspase 3 activation. Thus, increased Mdm2 expression is associated with transactivation at the P2 AP-1 RE (rather than the p53 or Ets REs), and Mdm2 induction potentially represents a cardioprotective response to oxidative stress.
- Published
- 2009
- Full Text
- View/download PDF
42. Are transgenic mice the 'alkahest' to understanding myocardial hypertrophy and failure?
- Author
-
Cook SA, Clerk A, and Sugden PH
- Subjects
- Animals, Cardiomegaly genetics, Extracellular Signal-Regulated MAP Kinases genetics, Extracellular Signal-Regulated MAP Kinases metabolism, Glycogen Synthase Kinase 3 genetics, Glycogen Synthase Kinase 3 metabolism, Heart Failure genetics, Mice, Mice, Transgenic, Ryanodine Receptor Calcium Release Channel genetics, Ryanodine Receptor Calcium Release Channel metabolism, Cardiomegaly metabolism, Heart Failure metabolism
- Abstract
Murine transgenesis using cardioselective promoters has become increasingly common in studies of cardiac hypertrophy and heart failure, with expression mediated by pronuclear microinjection being the commonest format. Without wishing to decry their usefulness, in our view, such studies are not necessarily as unambiguous as sometimes portrayed and clarity is not always their consequence. We describe broadly the types of approach undertaken in the heart and point out some of the drawbacks. We provide three arbitrarily-chosen examples where, in spite of a number of often-independent studies, no consensus has yet been achieved. These include glycogen synthase kinase 3, the extracellular signal-regulated kinase pathway and the ryanodine receptor 2. We believe that the transgenic approach should not be viewed in an empyreal light and, depending on the questions asked, we suggest that other experimental systems provide equal (or even more) valuable outcomes.
- Published
- 2009
- Full Text
- View/download PDF
43. Endothelin-1 regulation of immediate early gene expression in cardiac myocytes: negative feedback regulation of interleukin 6 by Atf3 and Klf2.
- Author
-
Clerk A, Cullingford TE, Fuller SJ, Giraldo A, and Sugden PH
- Subjects
- Activating Transcription Factor 3 genetics, Animals, Base Sequence, Endothelin-1 genetics, Feedback, Physiological, Gene Expression Profiling, Interleukin-6 genetics, Kruppel-Like Transcription Factors genetics, Molecular Sequence Data, Myocytes, Cardiac cytology, Oligonucleotide Array Sequence Analysis, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Rats, Rats, Sprague-Dawley, Signal Transduction physiology, Activating Transcription Factor 3 metabolism, Endothelin-1 metabolism, Gene Expression Regulation, Genes, Immediate-Early, Interleukin-6 metabolism, Kruppel-Like Transcription Factors metabolism, Myocytes, Cardiac physiology
- Published
- 2009
- Full Text
- View/download PDF
44. Nuclear Dbf2-related protein kinases (NDRs) in isolated cardiac myocytes and the myocardium: activation by cellular stresses and by phosphoprotein serine-/threonine-phosphatase inhibitors.
- Author
-
Fuller SJ, Pikkarainen S, Tham el L, Cullingford TE, Molkentin JD, Cornils H, Hergovich A, Hemmings BA, Clerk A, and Sugden PH
- Subjects
- Animals, Cells, Cultured, Cloning, Molecular, Enzyme Activation, Female, Marine Toxins, Myocardial Reperfusion Injury enzymology, Osmotic Pressure, Oxazoles pharmacology, Oxidative Stress, Protein Serine-Threonine Kinases chemistry, Protein Serine-Threonine Kinases genetics, Rats, Threonine metabolism, Enzyme Inhibitors pharmacology, Myocardium enzymology, Myocytes, Cardiac enzymology, Phosphoprotein Phosphatases antagonists & inhibitors, Protein Serine-Threonine Kinases metabolism
- Abstract
The nuclear Dbf2-related protein kinases 1 and 2 (NDR1/2) are closely-related AGC family kinases that are strongly conserved through evolution. In mammals, they are activated inter alia by phosphorylation of an hydrophobic domain threonine-residue [NDR1(Thr-444)/NDR2(Thr-442)] by an extrinsic protein kinase followed by autophosphorylation of a catalytic domain serine-residue [NDR1(Ser-281)/NDR2(Ser-282)]. We examined NDR1/2 expression and regulation in primary cultures of neonatal rat cardiac myocytes and in perfused adult rat hearts. In myocytes, transcripts for NDR2, but not NDR1, were induced by the hypertrophic agonist, endothelin-1. NDR1(Thr-444) and NDR2(Thr-442) were rapidly phosphorylated (maximal in 15-30 min) in myocytes exposed to some phosphoprotein Ser-/Thr-phosphatase 1/2 inhibitors (calyculin A, okadaic acid) and, to a lesser extent, by hyperosmotic shock, low concentrations of H(2)O(2), or chelerythrine. In myocytes adenovirally-transduced to express FLAG-NDR2 (which exhibited a mainly-cytoplasmic localisation), the same agents increased FLAG-NDR2 activity as assessed by in vitro protein kinase assays, indicative of FLAG-NDR2(Ser-282/Thr-442) phosphorylation. Calyculin A-induced phosphorylation of NDR1(Thr-444)/NDR2(Thr-442) and activation of FLAG-NDR2 were inhibited by staurosporine, but not by other protein kinase inhibitors tested. In ex vivo rat hearts, NDR1(Thr-444)/NDR2(Thr-442) were phosphorylated in response to ischaemia-reperfusion or calyculin A. From a pathological viewpoint, we conclude that activities of NDR1 and NDR2 are responsive to cytotoxic stresses in heart preparations and this may represent a previously-unidentified response to myocardial ischaemia in vivo.
- Published
- 2008
- Full Text
- View/download PDF
45. Differential regulation of Krüppel-like factor family transcription factor expression in neonatal rat cardiac myocytes: effects of endothelin-1, oxidative stress and cytokines.
- Author
-
Cullingford TE, Butler MJ, Marshall AK, Tham el L, Sugden PH, and Clerk A
- Subjects
- Animals, Animals, Newborn, Blotting, Western, Cells, Cultured, Hydrogen Peroxide pharmacology, Kruppel-Like Factor 4, Kruppel-Like Transcription Factors genetics, Myocytes, Cardiac cytology, Oxidants pharmacology, RNA, Messenger genetics, RNA, Messenger metabolism, Rats, Rats, Sprague-Dawley, Reverse Transcriptase Polymerase Chain Reaction, Signal Transduction, Transcription, Genetic, Endothelin-1 pharmacology, Gene Expression Regulation, Interleukin-1beta pharmacology, Kruppel-Like Transcription Factors metabolism, Myocytes, Cardiac drug effects, Myocytes, Cardiac metabolism, Oxidative Stress, Tumor Necrosis Factor-alpha pharmacology
- Abstract
Krüppel-like transcription factors (Klfs) modulate fundamental cell processes. Cardiac myocytes are terminally-differentiated, but hypertrophy in response to stimuli such as endothelin-1. H2O2 or cytokines promote myocyte apoptosis. Microarray studies of neonatal rat myocytes identified several Klfs as endothelin-1-responsive genes. We used quantitative PCR for further analysis of Klf expression in neonatal rat myocytes. In response to endothelin-1, Klf2 mRNA expression was rapidly increased ( approximately 9-fold; 15-30 min) with later increases in expression of Klf4 and Klf6 ( approximately 5-fold; 30-60 min). All were regulated as immediate early genes (cycloheximide did not inhibit the increases in expression). Klf5 expression was increased at 1-2 h ( approximately 13-fold) as a second phase response (cycloheximide inhibited the increase). These increases were transient and attenuated by U0126. H2O2 increased expression of Klf2, Klf4 and Klf6, but interleukin-1beta or tumor necrosis factor alpha downregulated Klf2 expression with no effect on Klf4 or Klf6. Of the Klfs which repress transcription, endothelin-1 rapidly downregulated expression of Klf3, Klf11 and Klf15. The dynamic regulation of expression of multiple Klf family members in cardiac myocytes suggests that, as a family, they are actively involved in regulating phenotypic responses (hypertrophy and apoptosis) to extracellular stimuli.
- Published
- 2008
- Full Text
- View/download PDF
46. ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium.
- Author
-
Fuller SJ, Sivarajah K, and Sugden PH
- Subjects
- Animals, Antineoplastic Agents pharmacology, Enzyme Activation drug effects, Humans, Ligands, Receptor Protein-Tyrosine Kinases chemistry, Signal Transduction drug effects, Myocardium enzymology, Receptor Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
The epidermal growth factor (EGF) receptor (or ErbB1) and the related ErbB4 are transmembrane receptor protein tyrosine kinases which bind extracellular ligands of the EGF family. ErbB2 and ErbB3 are "co-receptors" structurally related to ErbB1/ErbB4, but ErbB2 is an "orphan" receptor and ErbB3 lacks tyrosine kinase activity. However, both are important in transmembrane signalling. All ErbB receptors/ligands are intimately involved in the regulation of cell growth, differentiation and survival, and their dysregulation contributes to some human malignancies. After extracellular ligand binding, receptor dimerisation and transautophosphorylation of intracellular C-terminal tyrosine residues, they bind signalling proteins which recognise specific tyrosine-phosphorylated motifs. This leads to activation of multiple signalling pathways, notably the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade and the phosphoinositide 3-kinase (PI3K)/protein kinase B [PKB/(Akt)] pathway. In heart, targeted deletion of ErbB2, ErbB3, ErbB4 and some ErbB receptor extracellular ligands leads to embryonic lethality resulting from cardiovascular defects. ErbB receptor ligands improve cardiac myocyte viability and are hypertrophic, partly because of activation of ERK1/2 and/or PI3K/PKB(Akt). Furthermore, ErbB transactivation by Gq protein-coupled receptor (GqPCR) signalling may mediate the hypertrophic effects of GqPCR agonists. The utility of anthracyclines in cancer chemotherapy can be limited by their cardiotoxic side effects and these may be counteracted by ErbB receptor ligands. ErbB2 is the target of anti-cancer monoclonal antibody trastuzumab (Herceptin), and its myocardial downregulation may account for the occasional cardiotoxicity of this therapy. Here, we review the basic biochemistry of ErbB receptors/ligands, and emphasise their particular roles in the myocardium.
- Published
- 2008
- Full Text
- View/download PDF
47. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
- Author
-
Sugden PH, Fuller SJ, Weiss SC, and Clerk A
- Subjects
- Animals, Apoptosis physiology, Cardiomegaly pathology, Enzyme Inhibitors therapeutic use, Glycogen Synthase Kinase 3 antagonists & inhibitors, Glycogen Synthase Kinase 3 genetics, Histone Deacetylases metabolism, Humans, Myocytes, Cardiac enzymology, Myocytes, Cardiac pathology, Cardiomegaly drug therapy, Cardiomegaly enzymology, Glycogen Synthase Kinase 3 metabolism, Myocardium enzymology, Signal Transduction drug effects
- Abstract
Glycogen synthase kinase 3 (GSK3, of which there are two isoforms, GSK3alpha and GSK3beta) was originally characterized in the context of regulation of glycogen metabolism, though it is now known to regulate many other cellular processes. Phosphorylation of GSK3alpha(Ser21) and GSK3beta(Ser9) inhibits their activity. In the heart, emphasis has been placed particularly on GSK3beta, rather than GSK3alpha. Importantly, catalytically-active GSK3 generally restrains gene expression and, in the heart, catalytically-active GSK3 has been implicated in anti-hypertrophic signalling. Inhibition of GSK3 results in changes in the activities of transcription and translation factors in the heart and promotes hypertrophic responses, and it is generally assumed that signal transduction from hypertrophic stimuli to GSK3 passes primarily through protein kinase B/Akt (PKB/Akt). However, recent data suggest that the situation is far more complex. We review evidence pertaining to the role of GSK3 in the myocardium and discuss effects of genetic manipulation of GSK3 activity in vivo. We also discuss the signalling pathways potentially regulating GSK3 activity and propose that, depending on the stimulus, phosphorylation of GSK3 is independent of PKB/Akt. Potential GSK3 substrates studied in relation to myocardial hypertrophy include nuclear factors of activated T cells, beta-catenin, GATA4, myocardin, CREB, and eukaryotic initiation factor 2Bvarepsilon. These and other transcription factor substrates putatively important in the heart are considered. We discuss whether cardiac pathologies could be treated by therapeutic intervention at the GSK3 level but conclude that any intervention would be premature without greater understanding of the precise role of GSK3 in cardiac processes.
- Published
- 2008
- Full Text
- View/download PDF
48. Glycogen synthase kinases 3alpha and 3beta in cardiac myocytes: regulation and consequences of their inhibition.
- Author
-
Markou T, Cullingford TE, Giraldo A, Weiss SC, Alsafi A, Fuller SJ, Clerk A, and Sugden PH
- Subjects
- Animals, Benzazepines pharmacology, Cells, Cultured, Endothelin-1 physiology, Enzyme Inhibitors pharmacology, Extracellular Signal-Regulated MAP Kinases metabolism, Gene Expression Regulation, Enzymologic drug effects, Glycogen Synthase Kinase 3 antagonists & inhibitors, Glycogen Synthase Kinase 3 beta, Indoles pharmacology, Insulin pharmacology, Myocytes, Cardiac cytology, Phosphatidylinositol 3-Kinases metabolism, Phosphorylation drug effects, Rats, Rats, Sprague-Dawley, Signal Transduction drug effects, Tetradecanoylphorbol Acetate pharmacology, Transcription Factor AP-1 metabolism, Glycogen Synthase Kinase 3 metabolism, Myocytes, Cardiac enzymology
- Abstract
Inhibition of glycogen synthase kinase 3beta (GSK3beta) as a consequence of its phosphorylation by protein kinase B/Akt (PKB/Akt) has been implicated in cardiac myocyte hypertrophy in response to endothelin-1 or phenylephrine. We examined the regulation of GSK3alpha (which we show to constitute a significant proportion of the myocyte GSK3 pool) and GSK3beta in cardiac myocytes. Although endothelin increases phosphorylation of GSK3 and decreases its activity, the response is less than that induced by insulin (which does not promote cardiac myocyte hypertrophy). GSK3 phosphorylation induced by endothelin requires signalling through the extracellular signal-regulated kinase 1/2 (ERK1/2) cascade and not the PKB/Akt pathway, whereas the reverse is true for insulin. Cardiac myocyte hypertrophy involves changes in morphology, and in gene and protein expression. The potent GSK3 inhibitor 1-azakenpaullone increases myocyte area as a consequence of increased cell length whereas phenylephrine increases both length and width. Azakenpaullone or insulin promotes AP1 transcription factor binding to an AP1 consensus oligonucleotide, but this was significantly less than that induced by endothelin and derived principally from increased binding of JunB protein, the expression of which was increased. Azakenpaullone promotes significant changes in gene expression (assessed by Affymetrix microarrays), but the overall response is less than with endothelin and there is little overlap between the genes identified. Thus, although GSK3 may contribute to cardiac myocyte hypertrophy in some respects (and presumably plays an important role in myocyte metabolism), it does not appear to contribute as significantly to the response induced by endothelin as has been maintained.
- Published
- 2008
- Full Text
- View/download PDF
49. Temporal regulation of expression of immediate early and second phase transcripts by endothelin-1 in cardiomyocytes.
- Author
-
Cullingford TE, Markou T, Fuller SJ, Giraldo A, Pikkarainen S, Zoumpoulidou G, Alsafi A, Ekere C, Kemp TJ, Dennis JL, Game L, Sugden PH, and Clerk A
- Subjects
- Animals, Cells, Cultured, Endothelin-1 pharmacology, Gene Expression Profiling, Mitogen-Activated Protein Kinase 1 genetics, Mitogen-Activated Protein Kinase 3 genetics, Myocytes, Cardiac drug effects, Oligonucleotide Array Sequence Analysis, Protein Biosynthesis drug effects, Protein Biosynthesis genetics, RNA, Messenger analysis, RNA, Messenger metabolism, Rats, Signal Transduction, Transcription, Genetic, Endothelin-1 physiology, Gene Expression Regulation, Myocytes, Cardiac metabolism
- Abstract
Background: Endothelin-1 stimulates Gq protein-coupled receptors to promote proliferation in dividing cells or hypertrophy in terminally differentiated cardiomyocytes. In cardiomyocytes, endothelin-1 rapidly (within minutes) stimulates protein kinase signaling, including extracellular-signal regulated kinases 1/2 (ERK1/2; though not ERK5), with phenotypic/physiological changes developing from approximately 12 h. Hypertrophy is associated with changes in mRNA/protein expression, presumably consequent to protein kinase signaling, but the connections between early, transient signaling events and developed hypertrophy are unknown., Results: Using microarrays, we defined the early transcriptional responses of neonatal rat cardiomyocytes to endothelin-1 over 4 h, differentiating between immediate early gene (IEG) and second phase RNAs with cycloheximide. IEGs exhibited differential temporal and transient regulation, with expression of second phase RNAs within 1 h. Of transcripts upregulated at 30 minutes encoding established proteins, 28 were inhibited >50% by U0126 (which inhibits ERK1/2/5 signaling), with 9 inhibited 25-50%. Expression of only four transcripts was not inhibited. At 1 h, most RNAs (approximately 67%) were equally changed in total and polysomal RNA with approximately 17% of transcripts increased to a greater extent in polysomes. Thus, changes in expression of most protein-coding RNAs should be reflected in protein synthesis. However, approximately 16% of transcripts were essentially excluded from the polysomes, including some protein-coding mRNAs, presumably inefficiently translated., Conclusion: The phasic, temporal regulation of early transcriptional responses induced by endothelin-1 in cardiomyocytes indicates that, even in terminally differentiated cells, signals are propagated beyond the primary signaling pathways through transcriptional networks leading to phenotypic changes (that is, hypertrophy). Furthermore, ERK1/2 signaling plays a major role in this response.
- Published
- 2008
- Full Text
- View/download PDF
50. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses.
- Author
-
Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S, and Sugden PH
- Subjects
- Animals, Apoptosis genetics, Cardiomegaly genetics, Cardiomegaly pathology, Cardiomegaly physiopathology, DNA chemistry, DNA metabolism, Humans, MAP Kinase Signaling System genetics, Myocytes, Cardiac enzymology, Myocytes, Cardiac pathology, Nucleic Acid Conformation, Phosphoprotein Phosphatases genetics, Phosphoprotein Phosphatases metabolism, Protein Kinases genetics, Proto-Oncogene Proteins c-akt metabolism, Stress, Physiological complications, Stress, Physiological genetics, Stress, Physiological pathology, Stress, Physiological physiopathology, Transcription Factors genetics, Transcription Factors metabolism, Cardiomegaly metabolism, Gene Expression, Myocytes, Cardiac metabolism, Protein Kinases metabolism, Signal Transduction genetics, Stress, Physiological metabolism
- Abstract
The contractile cells in the heart (the cardiac myocytes) are terminally differentiated. In response to pathophysiological stresses, cardiac myocytes undergo hypertrophic growth or apoptosis, responses associated with the development of cardiac pathologies. There has been much effort expended in gaining an understanding of the stimuli which promote these responses, and in identifying the intracellular signaling pathways which are activated and potentially involved. These signaling pathways presumably modulate gene and protein expression to elicit the end-stage response. For the regulation of gene expression, the signal may traverse the cytoplasm to modulate nuclear-localized transcription factors as occurs with the mitogen-activated protein kinase or protein kinase B/Akt cascades. Alternatively, the signal may promote translocation of transcription factors from the cytoplasm to the nucleus as is seen with the calcineurin/NFAT and JAK/STAT systems. We present an overview of the principal signaling pathways implicated in the regulation of gene expression in cardiac myocyte pathophysiology, and summarize the current understanding of these pathways, the transcription factors they regulate and the changes in gene expression associated with the development of cardiac pathologies. Finally, we discuss how intracellular signaling and gene expression may be integrated to elicit the overall change in cellular phenotype.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.